Login to Your Account



Capsid-Targeting Approach for HBV, HIV Fetches Novira $23M

By Jennifer Boggs
Managing Editor

Friday, August 24, 2012

Over the past two years, the advent of protease inhibitors launched a paradigm shift that is changing the landscape of hepatitis C treatment. Now, 2009 biotech start-up Novira Therapeutics Inc. is looking to foster a similar revolution in hepatitis B, and its capsid-targeting approach got a boost last week with the closing of a $23 million Series A financing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription